EPO and chronic kidney disease: Renal patients, especially those with moderate-to-severe chronic kidney disease (CKD) are prone to hematological abnormalities, especially severe anemia, mainly due to the reduced secretion of erythropoietin and impaired erythrocyte survival in the uremic toxic environment.